Evotec receives CARB-X funding
Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8,4m funding from CARB-X for co-development of a first-in-class antibiotic.
Author Archive for: TG
About Thomas Gabrielczyk
This author has yet to write their bio.Meanwhile lets just say that we are proud Thomas Gabrielczyk contributed a whooping 416 entries.
Entries by Thomas Gabrielczyk
BioNTech and Fosun Pharma kick off Chinese COVID-19 trials
6th August 2020 in News /by Thomas GabrielczykBioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec partners with Secarna to develop LNA drugs
5th August 2020 in News /by Thomas GabrielczykEvotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
EC secures 300 million doses of COVID-19 vaccine
4th August 2020 in News /by Thomas GabrielczykThe European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine.
Roche’s IL-6 receptor blocker fails in Phase III
30th July 2020 in News /by Thomas GabrielczykRoche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Enthera Pharmaceuticals Srl raises 28m in Series A financing
29th July 2020 in News /by Thomas GabrielczykItalian start-up Enthera Pharmaceuticals has raised 28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.
Polyphor AG bags CHF19.3 in equity financing
28th July 2020 in News /by Thomas GabrielczykSwiss Polyphor AG has strengthened its financial flexibility with an equity-linked financing.
COVID-19: Siemens assay outperforms antibody tests from competitors
15th July 2020 in News /by Thomas GabrielczykIn a Public England Health study, Siemens Healthineers COV2T antibody test was the only assay found to meet both sensitivity and specificity requirements of the MHRA.
AMR: Big Pharma sets up US$1bn Fund
10th July 2020 in News /by Thomas GabrielczykAfter leaving the field of antimicrobials 20 years ago because other areas offered better returns, 23 pharma companies and the Novo Foundation have launched a US$1bn fund to fight antimicrobial resistance (AMR).
VarmX bags 32m in Series B round
9th July 2020 in News /by Thomas GabrielczykLeiden-based coagulant developer VarmX NV has closed a 32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X.